Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck noxafil (posaconazole, legacy) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2024
7
Period ended Dec 31, 2024
Change on a year earlier
-78.1%
32 in FY2023
History
9 years
Since FY2016
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Noxafil (posaconazole, legacy) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 7 | -78.1% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 32 | -37.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 51 | -15.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 60 | +42.9% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 42 | -85.1% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 282 | -20.1% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 353 | +14.2% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 309 | +8.8% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 284 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up noxafil (posaconazole, legacy) — u.s. sales ($m)
Cite this data
StockData. (2026). Merck Noxafil (posaconazole, legacy) — U.S. sales ($M) ($M), annual FY2016–FY2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_noxafil_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.